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ABSTRACT 
Objective: The main aim of the research was to develop a fast and highly sensitive bioanalytical LC-MS/MS technique for the quantitation of 
ibrutinib in human plasma.  
Methods: Chromatography has achieved on a reverse phase-symmetry C
, A. ASHOK KUMAR 
Mewar University, Chittorgarh, Rajasthan, India 
Email: jessie.hepsebah@gmail.com 
18 (75 mm × 4.6 mm, 3.5 µm) column with gradient elution by acetonitrile, 
methanol and 0.1%v/v formic acid as the mobile phase. Chromatographic peaks were resolved with 0.7 ml/min flow rate. Drug was extracted with 
ethyl acetate solvent by liquid-liquid extraction method. Monitoring of transition of m/z 441.2 and 55.01 for ibrutinib and 446.5 and 60.01 for 
Ibrutinib-D5 were made on multiple reaction monitoring. 
Results: Calibration curve of ibrutinib was linear over 1-600 ng/ml concentration range with a regression coefficient (r2
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) value of>0.99. The % RSD 
values were less than 8.5% for inter-day and intra-day precision and accuracy. The method has excellent recovery and the percentage recovery values of 
lower quality control (LQC), median quality control (MQC) and higher quality control (HQC) samples were 101.86%, 102.8%, and 99.28% respectively. 
Conclusion: The drug was stable for more time at variable stability conditions and method was successfully applicable to the regular analysis of 
ibrutinib in biological matrices. 




Ibrutinib is a small drug molecule that binds to a protein (Bruton’s 
tyrosine kinase) irreversibly, which is the most important protein in B-
cells. It is useful in the treatment of Waldenstrom's macro-
globulinemia, lymphocytic leukemia and second-line treatment for 
marginal zone lymphoma, chronic graft versus host disease and 
mantle cell lymphoma [1-3]. It is chemically designated as 1-[(3R)-3-
[4-Amino-3-(4-phenoxyphenyl)-1H–pyrazolo [3, 4-d] pyrimidin-1-yl] 
piperidin-1-yl] prop-2-en-1-one. It decreases chronic lymphocytic 
cancer cell chemotaxis and prevents cellular linkage followed by 
stimulus at the B-cell receptor (BCR) [4-6]. In addition, ibrutinib 
down-regulates the expression of CD-20 by pointing the CXCR-4/SDF-
1 axis [7]. Ibrutinib inhibits BCR-signaling, which initiates cells 
into apoptosis or interrupts cell movement and adhesion to protective 
cancer microenvironments. 
In the chronic lymphocytic leukemia (CLL) cell preclinical studies 
discloses that ibrutinib promotes apoptosis, prevent proliferation 
and inhibit CLL-cells response to survival stimulus from the 
microenvironment. This process leads to a decrease of Mcl-1(anti-
apoptotic protein) levels in malignant B-cells [7, 8].  
Drug literature review discloses that only a few analytical 
quantification methods for the ibrutinib in bulk, formulations, and 
biological matrices. The reported analytical techniques were HPLC 
[9-11] and LC-MS/MS [12, 13]. Goal of the research was to develop a 
fast and highly sensitive bioanalytical LC-MS/MS technique for the 
quantitation of ibrutinib in plasma samples and application of 
regulatory guidelines for method validation. 
MATERIALS AND METHODS 
Chemicals and reagents 
Ibrutinib (Purity: 99.84%) was procured from Hetero drugs PVT. 
LTD, Hyderabad, India. An internal standard (Ibrutinib-D5) of 
99.79% was obtained from MSN Labs, India. Acetonitrile of HPLC 
grade and formic acid of analytical grade were purchased from J. T. 
Baker, Hyderabad, India. In the present research work water used 
from Milli-Q water purification system installed in the lab obtained 
from Bangalore, India. 
 
 
Fig. 1: Structure of Ibrutinib 
 
LC-MS/MS system 
A modular Liquid Chromatographic (LC) system (Shimadzu, Japan) 
equipped with a DGU20-A3 solvent degasser, binary LC20-AD 
prominence pump,, CTO-ASVP oven for the column and high-
throughput SIL-HTC autosampler were utilized for present research. 
Chromatography was achieved on a Reverse Phase-Symmetry C18 
(75 mm×4.6 mm, 3.5 µm) column with gradient elution by 
acetonitrile, methanol, and 0.1% formic acid as the mobile phase. 
Chromatographic peaks were resolved by the mobile phase with a 
flow rate of 0.7 ml/min. Ibrutinib and ibrutinib-D5 internal standard 
were separated in the total runtime of 6 min. The autosampler 
temperature and analytical Column temperatures were kept at 5 °C 
and 35 °C respectively.  
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The eluents of the liquid chromatographic system were infused 
into the ElectroSpray Ionization (ESI) source operated with 
positive ionization method. Starting 0.5 min eluent was avoided 
from the chromatographic system to evade unnecessary 
impurities from the various salts existed in the human plasma 
samples. 
In the mass system following conditions were applied; gas-1, nitrogen 
(40 psi); gas-2, nitrogen (40 psi); temperature of ion source, 400 °C; 
curtain-gas, nitrogen (25 psi); voltage of ion spray, 5000 V. Monitoring 
of transition of m/z 441.2 and 55.01 for ibrutinib and 446.5 and 60.01 
for ibrutinib-D5 were made on multiple reaction monitoring(MRM). 
The mass conditions were presented in table 1. 
  
Table 1: Mass conditions for ibrutinib and IS 
Compound Precursor Ion (m/z) Product Ion (m/z) DP (V) EP (V) CEP (V) CE (V) CXP (V) 
Ibrutinib 441.2 55.01 40 8 25 30 5 
Ibrutinib-D5 446.5  60.01  100 8 25 82 5 
DP: Declustering potential; EP: Entrance potential; CEP: Collision cell entrance potential; CE: Collisional energy; CXP: Collision cell exit potential. 
 
Preparation of standard stock and calibration standards  
Stock solutions ibrutinib and IS were processed in 70% methanol at 
the concentration level of 1000 µg/ml. Quality control(QC) and 
calibration standard(CC) solutions were processed by spiking blank 
human plasma sample from the ibrutinib stock solution. CC 
solutions of eight concentration levels were prepared to produce the 
final concentrations of 1.0, 5.0, 25.0, 50.0, 100.0, 150, 300 and 
600ng/ml. LQC standard, MQC standard, and HQC standards were 
QC sample solutions and were prepared to produce the 
concentrations of 2, 200 and 500 ng/ml respectively. All the stock, 
CC and QC solutions were stored at-20℃ till the method of analysis. 
Sample preparation 
To 250 µl of spiked plasma, 50 µl of Ibrutinib-D5 (1µg/ml) was 
mixed and sonicated for 15 seconds. To the resulting solution, 500 µl 
of ethyl acetate was added and vortexed for five min, followed by 
centrifuged at 5000 rpm for 10-20 min at 5 °C. The organic phase 
was dried in a lyophiliser. The final residue was dissolved in 200 µl 
of mobile phase and transferred into a pre-labeled Autosampler vial 
and infused into an LC-MS/MS system.  
Validation 
The method of analysis was assessed by validation parameters like 
sensitivity, precision, linearity, recovery, dilution integrity, accuracy, 
matrix effect, and stability. Three QC samples of LQC, MQC and HQCs 
as well as LLOQ (Lower Limit of Quantification) were employed and 
analyzed in method validation [14, 15].  
Specificity and selectivity 
Method selectivity was analyzed by comparing the chromatograms 
obtained from blank and spiked solutions. Method specificity was 
analyzed by infusing six different lots of blank plasma solutions to 
ensure no endogenous compounds interfere with ibrutinib and 
internal standard (IS).  
Linearity 
CC standards (Non-zero) of 8 different concentrations at 1.0, 5.0, 
25.0, 50.0, 100.0, 150, 300 and 600 ng/ml were prepared and 
analyzed in three separate runs. Linearity curve (peak area ratio of 
ibrutinib and ibrutinib-D5 peaks against nominal concentration) 
were plotted by least squares linear regression and reciprocal of the 
squared concentration (1/x2) used as a weighting factor. Deviation 
should be within±20% for LLOQ and±15% for remaining 
concentrations. 
Precision and accuracy 
Intra-day and inter-day precision and accuracy were examined as a 
part of the precision and accuracy (PA) parameter. Intra-day PA was 
evaluated by injecting QC solutions (2, 200 and 500 ng/ml) and 
LLOQ (1.0 ng/ml) in 5 replicates in a day arbitrarily. Inter-day PA 
was evaluated by injecting the same QC and LLOQ solutions once in a 
day for 5 different days. The % RSDs for LQC, MQC, and HQCs should 
be ≤ 20% for LLOQ and ≤ 15% for the remaining QC standards [16].  
Recovery and matrix effect (ME) 
Ibrutinib recovery was evaluated by paralleling the mean peak areas 
of extracted and un-extracted samples at low, medium and high QC 
standard levels. At each concentration level percentage recoveries 
was calculated and finally, overall mean recovery was calculated. 
The ME was analyzed by paralleling the un-extracted samples with 
post-extracted samples [17, 18]. 
% Recovery of ibrutinib
=
Mean ibrutinib peak response in extracted samples
Mean ibrutinib peak response in un − extracted samples
 × 100 
Dilution integrity 
The sample solution above the upper limit of calibration range was 
prepared and evaluated for PA parameters. The percentage nominal 
concentration must be±15 %.  
Stability 
Stability was analysed at LQC, MQC, and HQC quality control levels. 
It includes bench-top, freeze-thaw, autosampler and long term 
stabilities. The bench-top stability was evaluated for 5 h at ambient 
temperature (25 ℃). Freeze and thaw stability was analyzed by 
storing the QC samples at-70 ℃ for at least 3 h and for thaw cycle 
keep the solutions at room temperature. Repeat the freeze and thaw 
cycles for 3 times. The autosampler stability was analyzed by placing 
the QC solutions in autosampler at 10-degree centigrade for 8 h. 
Long term stability was evaluated by placing the QC samples in a 
freezer at-70 ℃  for three months [19, 20]. 
RESULTS AND DISCUSSION 
The LC-MS/MS chromatograms of ibrutinib blank, LLOQ, LQC, MQC 
and HQC concentration levels were shown in fig. 2 and fig. 3. 
Method validation 
Specificity 
From the fig. 2 and 3, system chromatographic conditions were 
clearly separating ibrutinib and internal standard from endogenous 
and other plasma substances. The ibrutinib-LLOQ peak response is 
more than 20% the interference peak response and ibrutinib-D5 
peak response is more than 5% from the interference peak 
response.  
Linearity 
Ibrutinib calibration graph was linear in the concentration range of 
1to 600 ng/ml with the regression equation of Y = 0.4528 X+3.145. 
The regression coefficient (r2
Ibrutinib inter-day and intra-day precision and accuracy were 
analyzed and the % RSD values were calculated for the same and 
were tabulated in the table 2. 
) value is more than 0.99 which was 
acceptable as per the FDA regulatory guidelines [14].  
Precision and accuracy 
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Fig. 2: Chromatograms of (A) blank plasma and (B) spiked LLOQ samples 
 
Table 2: Ibrutinib precision and accuracy data 
Nominal concentration (ng/ml) Intra-day Inter-day 
Accuracy (%) %RSD Accuracy (%) %RSD 
1 104.6 4.5 107.5 5.2 
2 89.6 3.9 91.6 6.1 
200 105.2 2.5 101.2 4.2 
500 109.8 8.1 96.4 2.9 
 
Recovery and matrix effect (ME) 
The method has an excellent recovery and the percentage recovery 
values were 101.86%, 102.8%, and 99.28% for LQC, MQC and HQC 
quality control samples respectively. The data for ibrutinib recovery 
were tabulated in table 3. The matrix effect was evaluated at LQC 
and HQC level and the calculated %CV values were 4.59% and 3.68% 
respectively.
 
Hepsebah et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 3, 22-26 
25 
 
Fig. 3: Chromatograms of ibrutinib spiked (A) LQC, (B) MQC and (C) HQC samples 
 
Table 3: Recovery data for ibrutinib 





















1 0.213 0.251 117.85 0.648 0.634 98.451 0.897 0.885 98.66 
2 0.246 0.235 95.59 0.612 0.65 106.20 0.905 0.879 97.12 
3 0.254 0.249 98.03 0.598 0.635 106.18 0.856 0.985 115.07 
4 0.217 0.215 99.08 0.688 0.643 93.45 0.956 0.912 95.39 
5 0.214 0.219 102.34 0.675 0.684 101.33 0.965 0.845 87.56 
6 0.243 0.239 98.35 0.598 0.665 111.20 0.895 0.912 101.89 
Mean 0.23 0.24 101.86 0.64 0.6525 102.80 0.912 0.903 99.28 
SD 0.017 0.014 7.42 0.02 0.017 5.80 0.037 0.04 8.301 
%CV 7.29 5.83 7.28 5.68 2.62 5.64 4.11 4.77 8.36 
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Bench-top stability Autosampler stability Freeze and thaw 
 stability 




%CV mean±SD  
(ng/ml) 
%CV mean±SD  
(ng/ml) 





2 2±0.4 10.8 2±0.3 6.5 2±0.2 5.2 2±0.2 6.2 
200 200±18.0 9.4 200±11.0 8.9 200±9.0 4.9 200±11.0 5.2 
500 500±21 6.4 500±8.0 4.2 500±7.2 9.5 500±12.0 8.4 
 
Dilution integrity 
Dilution integrity of ibrutinib was performed and evaluated. The 
percentage nominal was within the limit (±15%) and the estimated 
precision was less than or equals to 15%. It shows that the drug can 
be dilute to twenty times and the results will be reproducible. 
Stability 
All the QC standards were exposed to different stability conditions 
and evaluated to analyse the stability of ibrutinib. From evaluated 
%CV stability data, the drug was stable for more time at variable 
conditions like bench-top stability (<10.8%), freeze-thaw stability 
(<9.5%), autosampler stability (<8.9%) and long term stability 
(<8.4%) and the values were presented in table 4. 
CONCLUSION 
A bioanalytical LC-MS/MS method for the ibrutinib was developed 
and validated with Ibrutinib-D5 as IS. This method has excellent 
recovery, accuracy, and precision compared with existed methods 
for the analysis of drug in human plasma samples. The drug was 
extracted from plasma samples by liquid-liquid extraction (LLE) 
method with ethyl acetate as an extraction solvent. The drug was 
eluted within 6 min using Reverse Phase-Symmetry C18 
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